Abstract Background and aims Platform trials are an efficient trial design which enables the testing of multiple interventions simultaneously. We aimed to investigate the views of clinicians involved in stroke research on recruitment to a future platform trial for ICH. Methods Between April and July 2025, we conducted a UK-wide online survey of clinicians actively involved in stroke research. Participants considered factors related to the consent process and research environment and provided optional free text responses about barriers and facilitators to recruitment. We used descriptive statistics for quantitative data and content analysis for qualitative data. Results Among 73 respondents, 46 (63%) were female, 36 (50%) were stroke physicians, 24 (34%) nurses, 6 (8%) allied health professionals, and 7 (10%) were in other roles. 36 (49%) had 20 years’ clinical experience, 45 (61%) reported spending 10% of their role in research. 66 (91%) of respondents believed a platform trial would be a good option for testing interventions for patients with stroke due to ICH. Across 11 modifiable factors, clinicians most frequently rated perceived importance of the research question as a facilitator of recruitment (94%), while clinician preference for specific treatments was most frequently rated as a barrier (48%). Respondents identified factors affecting recruitment relating to infrastructure and study design. The study design factors comprised consent procedures (n=9) and accessible study materials (n=8), alongside study procedures (n=8), identifying eligible patients (n=6), the research question (n=3) and randomization (n=3). Conclusions The overwhelming majority of respondents from the UK clinical stroke community supported a platform trial for ICH. Conflict of interest
Boldbaatar et al. (2026) studied this question.